Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463526 | 1.00 | HDAC1 (0.67) | HDAC1HDAC6 | |
| SCHEMBL191156 | 0.88 | HDAC1 (0.58) | HDAC1HDAC6 | |
| SCHEMBL191155 | 0.88 | HDAC1 (0.58) | HDAC1HDAC6 | |
| SCHEMBL2156643 | 0.88 | HDAC1 (0.58) | HDAC1HDAC6 | |
| SCHEMBL192977 | 0.85 | HDAC1 (0.50) | HDAC1HDAC6 | |
| SCHEMBL192627 | 0.85 | HDAC1 (0.50) | HDAC1HDAC6 | |
| SCHEMBL192626 | 0.85 | HDAC1 (0.50) | HDAC1HDAC6 | |
| SCHEMBL16270392 | 0.84 | HDAC1 (0.63) | HDAC1HDAC6 | |
| SCHEMBL11328111 | 0.83 | ALDH1A1 (0.53) | HDAC1HDAC6 | |
| SCHEMBL12672870 | 0.82 | HDAC1 (0.63) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | HDAC1 1/4885HDAC6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.